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Summary 
AMP activated protein kinase (AMPK) is a critical energy sensor, regulating signaling 
networks involved in pathology including metabolic diseases and cancer. This increasingly 
recognized role of AMPK has prompted tremendous research efforts to develop new 
pharmacological AMPK activators. To precisely study the role of AMPK, and the specificity 
and activity of AMPK activators in cellular models, genetic AMPK inactivating tools are 
required. We report here methods for genetic inactivation of AMPK 1/ 2 catalytic subunits 
in human cell lines by the CRISPR/Cas9 technology, a recent breakthrough technique for 
genome editing. 
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1. Introduction 
 
1.1 CRISPR/Cas9 genome-editing system 
The rapid development of the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/ CRISPR associated protein 9 endonuclease (Cas9) technology provides 
unprecedented genomic research tools. CRISPR are short DNA sequences found in bacteria. 
Together with the bacterial Cas9 these sequences are involved in the clearance of foreign 
DNA from bacteria [1]. Shortly after its discovery, the CRISPR/Cas9 system has been 
engineered for genome editing including in eukaryotic cells. Indeed, CRISPR/Cas9 offers a 
specific genomic tool based on the complementation of genomic DNA by a 20-mer 
 3 
oligonucleotide sequence followed by a consensus sequence called PAM for protospacer 
adjacent motif. This guide RNA (sgRNA) allows the recruitment of Cas9 to the targeted 
genomic DNA sequence leading to DNA double strand breaks (DSB). In case of DSB repair 
by non homologous end joining (NHEJ), small insertions/deletions within coding sequences 
may be produced leading to a premature stop codon [2,3]. Alternatively, DSB may be repaired 
by homologous recombination (HR), which may be exploited for targeted mutagenesis of 
endogenous genes when using a mutated recombination template [4]. In fact, multiple 
refinements of the CRISPR/Cas9 technology have been described and the power of these 
techniques as well as their potential applications is increasingly growing. 
 
1.2 Why and how disrupting AMPK activity? 
AMP-activated protein kinase (AMPK) is one of the main cellular energy sensor, activated by 
the binding of AMP or ADP to its γ-regulatory subunit and by the phosphorylation of its α-
catalytic subunit [5]. Once activated, AMPK modifies cell metabolism (inhibition of 
anabolism and activation of catabolism) to restore cellular energy balance. Tremendous 
research efforts are therefore ongoing to efficiently activate AMPK in the context of 
metabolic diseases or cancer [5]. Abrogating AMPK activity may help to define the role of 
AMPK in a given cellular context. Unfortunately, no specific AMPK inhibitors are currently 
available and genetic knockdown/knockout approaches are recommended to validate the 
function of AMPK (see Chapter 12). Hence, specific deletion of AMPK genes represents an 
invaluable tool to assess the specificity of AMPK-targeting small molecules (mostly AMPK 
activators). While targeting regulatory AMPKβ or γ subunits may be important to disrupt the 
regulation of AMPK activity and function, AMPKα gene inactivation is sufficient to abrogate 
AMPK serine/threonine kinase activity [6]. At first glance, we used RNA interference (RNAi) 
by small hairpin RNA (shRNA) to deplete AMPKα from acute myeloid leukemia (AML) 
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cells as done by other groups in other cellular contexts [7-9]. However, we failed to achieve a 
complete inhibition of AMPKα, with a residual expression of 10-20% at the protein level [10]. 
Indeed, Saito and colleagues recently demonstrated the essential pro-survival function of 
AMPK in AML cells exposed to stress [11], thus explaining the negative selection of cells 
with efficient AMPK1 knockdown. Hence, efficient and stable AMPK knockout in human 
cell lines represents a challenge. To avoid this limitation, and also to reduce the probability of 
off-target as observed with shRNA [12], we moved towards a CRISPR/Cas9-based approach 
to study AMPK function in human cell lines. In this chapter, we describe the use of 
CRISPR/Cas9 technology to disrupt AMPKα
MOLM-14 and OCI-AML3 cells, and concomitant AMPKα α2 expression in 
colon carcinoma Caco2 cells that may provide invaluable tools for further studies on AMPK 
biology and development of specific AMPK activators for the treatment of cancer and 
metabolic diseases. We attempted to find common DNA sequences across PRKAA1 and 
PRKAA2 genes (encoding the AMPK1 and AMPK2 catalytic subunits, respectively) for 
targeting by a single sgRNA, but no such sequence was available within PRKAA1 or PRKAA2 
coding or non-coding DNA. While multiplexing sgRNA into a single vector is possible [13], 
we used a sequential procedure to achieve first AMPKα1 and then AMPKα2 knockdown in 
single-cell clones. We thus developed PRKAA1- and PRKAA2-targeting CRISPR/Cas9 
systems allowing a convenient sequential selection of AMPKα -depleted single cell clones 
based on antibiotic resistance, and then isolation of AMPKα2 knockout single-cell clones 
based on the expression of a fluorescent marker. In particular, we describe procedures to 
design AMPKα α2 targeting sgRNAs, and cloning into lentiviral vector. We also 
provide methods for infection, clonal selection, screening and validation of single-cell 
CRISPR clones.  
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2. Material 
2.1 sgRNA design and cloning 
1. Online bioinformatic sgRNA design tool (eg, CRISPR design tool). (See note 3). 
2. lentiCRISPR v2 plasmid (Addgene reference #52961. (See notes 4 and 5). 
3. pL-CRISPR.EFS.GFP plasmid (Addgene reference #57818). 
4. Designed sgRNA oligonucleotides: 100 µM oligonucleotides in H2O. 
- PRKAA1 sgRNA#1: forward 5'-CACCGAGGGCACGCCATACCCTTG-3' and 
reverse 5'-AAACCAAGGGTATGGCGTGCCCT-3'. 
- PRKAA1 sgRNA#2: forward 5'- CACCGATCCTGAAAGAGTACCATTC -3' and 
reverse 5'- AAACGAATGGTACTCTTTCAGGAT-3'. 
- PRKAA2 sgRNA#1: forward 5'-CACCGAAGATCGGACACTACGTGCT-3' and 
reverse 5'-AAACAGCACGTAGTGTCCGATCTTC-3'. 
- PRKAA2 sgRNA#2: forward 5'-CACCGTCAGCCATCTTCGGCGCGCG-3' and 
reverse 5'-AAACCGCGCGCCGAAGATGGCTGAC-3'. 
5. 10X kinase buffer: 500 mM Tris-HCl, pH 7.6, 100 mM MgCl2, 50 mM DTT, 10 mM 
ATP, 1 mM spermidine. 
6. T4 PNK: 10 U/µl T4 polynucleotide kinase. 
7. Restriction enzyme: 10 U/µl EspI (BsmBI) and 10X FastDigest green buffer 
(ThermoFisher scientific). 
8. T4 ligase: 1 U/ µl T4 ligase. 
9. 10X ligation buffer: 500 mM Tris-HCl, pH 7.5, 100 mM MgCl2, 10 mM ATP, 10 mM 
DTT, 50% (w/v) polyethylene glycol-8000. 
10. Stbl3 Escherichia coli competent cells. 
11. SOC medium: 20 g/l tryptone, 5 g/l yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose. Dissolve to 1 L deionised water, 20 g of 
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tryptone, 5 g of yeast extract, 2 ml of 5 M NaCl, 2.5 ml of 1 M KCl, 10 ml of 1 M 
MgCl2, and 10 ml of 1 M MgSO4. Autoclave at 121°C for 15 min and add 20 ml of 
filter-sterilized 1 M glucose. 
12. LB agar plate: lysogeny broth (LB) agar plate with 100 μg/ml ampicillin. 
13. Maxiprep plasmid DNA kit. 
 
2.2 Production of lentiviral particles 
Before starting work with lentivirus, ensure compliance with your Environmental Health and 
Safety office and government/organization/university.  
14. HEK 293T cells. 
15. Phosphate buffer saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4, pH 7.4. 
16. CaCl2 solution: 1 M CaCl2. 
17. Lipofectamine 2000 transfection reagent. 
18. PsPAX2 plasmid (encoding Gag and Pol proteins). (Addgene reference #12260). 
19. pMD2.G (encoding VSVG envelope proteins). (Addgene reference #12259). 
20. HEPES buffered saline (HBS): 20 mM HEPES, pH 7, 150 mM NaCl. 
21. Complete DMEM medium: DMEM, 10% (v/v) foetal bovine serum (FBS), 100 
units/ml penicillin and 100 µg/mL streptomycin, 2 mM L-Glutamine. 
22. Complete MEM alpha medium: MEM alpha medium, 10% (v/v) foetal bovine serum 
(FBS), 100 units/ml penicillin and 100 µg/mL streptomycin, 2 mM L-Glutamine. 
23. OPTIMEM culture medium. 
24. 0.22 µm filter. 
25. G418 (Geneticin) stock solution: 100 mg/ml G418. 
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2.3 Infection and clone selection 
26. Human AML cell lines: MOLM-14 or OCI-AML3 human cell lines. 
27. Human Caco2 colon carcinoma cell line. 
28. Complete MEM alpha medium: Minimum Essential Medium (MEM) alpha medium, 
10% (v/v) FBS, 100 units/ml penicillin and 100 µg/mL streptomycin, 2 mM L-
Glutamine. 
29. Complete EMEM culture medium: Eagle's Minimum Essential Medium (EMEM), 
20 % (v/v) FBS, non-essential amino acids, 100 units/ml penicillin and 100 µg/mL 
streptomycin. 
30. Trypsin/ EDTA solution: 0.25% (w/v) Trypsin, 0.53 mM EDTA. 
31. 50 µm cell strainer. 
32. Cell sorting buffer: PBS (without Ca2+/Mg2+), 25 mM HEPES, pH 7, 1% (v/v) FBS, 1 
mM EDTA. 
33. 12 ml FACS tube 
34. Flow cytometer. 
 
2.3 Screening 
35. GeneScan™ 500ROX 
36. PCR Primers: 
- PRKAA1 primers: forward 5'-FAM-ATCACCAGGATCCTTTGGCA-3' and reverse 
5'-TGCTTTCCTTACACCTTGGTG-3'. 
- PRKAA2 primers: forward 5'-FAM-GCTGCACTGTGGGTAGGC-3' and reverse 5'-
GGGCGTCGGCACCTTC-3'. 
37. Capillary electrophoresis. 
38. GeneMapper® software v3.7 
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2.4 Sequencing 
39. Sequencing primers: 
- PRKAA1 primers: forward 5'-ATCACCAGGATCCTTTGGCA-3' and reverse 5'-
TGCTTTCCTTACACCTTGGTG-3'. 
- PRKAA2 primers: forward 5'-GCTGCACTGTGGGTAGGC-3' and reverse 5'-
GGGCGTCGGCACCTTC-3'. 
40. Cell lysis buffer: 4% Tween 20,100 µg/ml proteinase K in H2O. 
41. DNA polymerase: Phire Hot Start II DNA polymerase and 5X reaction buffer (Thermo 
scientific). 
42. Tris acetate EDTA (TAE) buffer: 40 mM Tris-HCl, pH 8.3, 20 mM acetic acid, 1 mM 
EDTA. 
43. Agarose gel: 2% (w/v) agarose in TAE. 
 
3. Methods 
3.1. sgRNA design and cloning 
Putative target sites can be identified by simply scanning the region of the particular genomic 
location that you want to target (but you should check your sgRNA design for potential off- 
target effects) or by using online bioinformatical tools dedicated to sgRNA design. (See note 
3). 
Human AMPKα catalytic subunit encompasses two isoforms, AMPKα1 and AMPKα2, 
encoded by the PRKAA1 and PRKAA2 genes located at chromosomes 5p13.1 and 1p32.2, 
respectively. PRKAA1 is made of 9 exons (Figure 1A) representing 5088 base pairs (bp), and 
encodes a 559 aminoacids (AA) protein of 64 kDa. PRKAA2 coding sequence is 9280 bp-long 
but with a long 3’ untranslated region, and encodes a 552 AA protein of 62 kDa (Figure 1B). 
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To target PRKAA1 gene, we designed 2 sgRNAs targeting PRKAA1 exon 7. To target 
PRKAA2 gene, we designed 2 sgRNAs targeting PRKAA2 exon 1 (Figure 1A and B). 
 
[Figure 1 near here] 
 
CRISPR design 
1. Identify sgRNA targeting sequences in the genomic region of interest by running the 
CRISPR design tool (See notes 6, 7 and 8). The output window shows 23 bp genomic 
sites of the form 5'-N20NGG-3' within your target region. These sites may reside on the + 
or -strand (Figure 2). 
2. Remove NGG sequence to leave 20 nt target sequence.  
3. Add G to the 5’ end of target sequence if it does not begin with G. (See note 9). 
4. For cloning into the plentiCRISPR vector using BbsI restriction enzyme, add GATC to 
the 5’ end of forward oligonucleotide, and add AAAA to the reverse complement 
oligonucleotide (including any additional G nucleotide). (See note 10). 
5. Synthetize forward and reverse oligonucleotides corresponding to the selected sgRNAs. 
(See notes 11 and 12) 
CRISPR cloning 
6. Mix 1 µl of 100 µM of forward and reverse oligonucleotides with 1 U of T4 PNK in 10 
µl of 1X kinase buffer and incubate for 30 min at 37°C. (See note 13). 
7. Incubate at 95°C for 5 min and gradually cool the solution at room temperature. 
8. Digest 5µg of plentiCRISPR v2 plasmid backbone with 30 U of Esp3I (BsmBI) in a final 
volume of 60µl of 1X FastDigest green buffer. Incubate for 25 min at 37°C, and then at 
65°C for 15 min. (See note 14) 
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9. Prepare a 10 µl ligation reaction mix by adding 150 ng of plentiCRISPR digestion 
product, 1 µl of 1 µM annealed sgRNA oligonucleotides, 1 µl of 1 U/µl T4 ligase, 1µl of 
10X T4 ligase buffer. Incubate for 10 to 30 min at room temperature.  
10. Transform the ligation product into Stbl3 Escherichia coli (See note 15). 
11. Incubate ligation product and one aliquot of Stbl3 cells for 10 minutes on ice. 
12. Heat-shock at 42°C for 45 seconds and return to ice for 2 min. 
13. Add 250 μl of room temperature SOC medium and incubate at 37°C with shaking for 1 h. 
14. Spread the transformation mixture onto a prewarmed LB agar plate containing 100 μg/ml 
kanamycin. Incubate overnight at 37°C. 
15. Incubate the plates overnight at 37 °C in a microbiological incubator. 
16. After incubation, pick 5 to 10 colonies to identify a correct clone for proper insert 
identification by Sanger sequencing. 
17. After identifying the colonies with the correct sequence, isolate plasmid DNA using a 
maxiprep kit. 
 
[Figure 2 near here] 
 
3.2 Lentivirus production 
To produce recombinant lentivirus, HEK293-T packaging cells are transfected with the 
packaging plasmids pVSVg and psPAX2 encoding lentiviral proteins (Gag, Pol and Env) and 
the transfer plentiCRISPR/ sg RNA plasmid. We propose here two different methods for 
lentiviral particles production using HEK293T packaging cells. (See note 16). 
 
Calcium/HBS transfection 
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18. Plate 1.5x106 HEK293T cells into two T175 flask in complete DMEM medium 
containing 1 mg/ml G418 antibiotic (generally 4 days before transfection). 
19. The day of transfection, wash cells once with PBS and add 18 ml of DMEM without FBS 
or G418. Incubate the cells for 6h in a humidified 37°C, 5% CO2 incubator. 
20. Prepare transfection solution by adding 1.5 ml of sterile water, 500 µl of 1 M CaCl2 
solution and a DNA plasmid mix containing 16 µg pMD2.G, 24 µg PsPAX2 and 3µg of 
plentiCRISPR/ sgRNA plasmids. 
21. During a continuous vortex agitation, add dropwise transfection solution into 2 ml of 
HBS in a 50 ml tube. Incubated the mixture (final volume of 4 ml) for 15 min at room 
temperature. 
22.  Add 2ml of this mix on each T175 flask and incubate overnight in a humidified 37°C, 
5% CO2 incubator. 
23. Discard culture medium and add 18 ml of complete DMEM culture medium. Incubate in 
a humidified 37°C, 5% CO2 incubator for 24h. 
24. Collect the supernatants using a syringe and filtrate out the cellular debris using a 0.22µm 
filter. The filtered lentivirus supernatant can be either immediately used to transduce a 
cell line or stored at -80°C. Avoid freeze-thawing lentivirus supernatant. (See note 17). 
 
Lipofectamine transfection 
25. Plate 2x106 HEK293T cells into two 10 cm diameter culture dishes with DMEM culture 
medium containing 1 mg/ml G418 antibiotic and incubate overnight in a humidified 37°C, 
5% CO2 incubator. 
26. Wash once with PBS and replace medium with 4.2 ml of OPTIMEM culture medium. 
27.  Add 12µl of lipofectamine 2000 transfection reagent to 400µl of FBS-free OPTIMEM 
medium. Incubate the mixture at room temperature for 15 min. 
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28. Add 3µg of plentiCRISPR/ sgRNA, 2µg of PsPAX2 vector and 1µg of pMD2.G plasmids 
to 400µl of FBS-free OPTIMEM medium.  
29. Mix diluted plasmid DNA with diluted Lipofectamine mixture. Incubate the mixture at 
room temperature for 15 min. 
30. Add 800 µl of the mixture dropwise to the cells and incubate in a humidified 37°C, 5% 
CO2 incubator. 
31.  Replace medium after 3-6 h with fresh DMEM culture medium and incubate in a 
humidified 37°C, 5% CO2 incubator for 48 h. 
32. Collect the supernatants using a syringe and filtrate out the cellular debris using a 0.22µm 
filter. The filtered lentiviral supernatant can be either immediately used to transduce a 
cell line or stored at -80°C. Avoid freeze-thawing lentiviral supernatant. (See note 17). 
 
3.3 Cell infection and clonal isolation  
Determination of MOI 
The volume of supernatants used for infection may vary for each cell line and depends on 
lentiviral titer. Determination of the multiplicity of infection (MOI) for each cell line is 
recommended and is valid only for a given lentiviral supernatant batch [14]. To ensure that 
most cells receive only one stably-integrated sgRNA, a MOI of 0.3 should be used. (See note 
18). 
MOI theoretically is the number of viral particles per cell, a MOI of 1 meaning that 1 particle 
reached a single cell. However, particles may not lead to viral genome integration in all cases 
and transduction is not linear but follows a Poisson distribution considering that each event is 
independent. MOI can be determined by using the following formula: 
m = -ln(1-P)  
where m = MOI and P = probability of infection. 
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33. Plate 12-well plates at a density of 2x105/ml AML cells in 2 ml of complete MEM 
alpha medium.  
34. In each well, add 200 µl, 100 µl, 50 µl, 25 µl or 0 µl of lentiviral supernatant. An 
additional no antibiotic selection control well without addition of lentivirus is prepared. 
Incubate for 24 h in a humidified 37°C, 5% CO2 incubator. 
35. 24 h after lentiviral transduction, wash the cells twice with PBS to eliminate residual 
lentiviral particles, and then incubate with complete MEM alpha medium. 
36. 24 h after lentiviral transduction, replace the medium with complete MEM alpha 
medium containing 1 mg/ml puromycin (or the relevant antibiotic selection). For the no 
antibiotic selection control well, replace the medium with complete MEM alpha medium 
without antibiotic. 
37. Refresh complete MEM alpha medium with and without antibiotic until the antibiotic 
selection control well with no virus contains no viable cells. 
38. Count the number of cells in each well. For each virus conditions, MOI is estimated. 
For example, if 37% of transduced cells are recovered after antibiotic selection, MOI = -
ln(0.37) = 0.994. 
 
Infection of cell lines 
39. For AML human cell lines, seed cells at a density of 2x105 cells/ml in complete MEM 
alpha medium. 
40. For colon carcinoma Caco2 cells, plate 2x105 cells/ well in 24-well plate in 0.5 ml of 
complete EMEM culture medium. 
41. Add lentiviral supernatants at a MOI of 0.3 and incubate for 24 h in a humidified 37°C, 
5% CO2 incubator. 
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42. Wash the cells with PBS twice and then incubate with complete MEM alpha medium for 
AML cells or complete EMEM culture medium for Caco2 cells. 
 
Antibiotic selection and clonal isolation 
43.  Two to three days after lentiviral transduction, replace the medium with complete MEM 
alpha medium containing 1 mg/ml puromycin (or relevant antibiotic selection depending 
on antibiotic resistance marker expressed on the lentivirus vector used) for AML cells or 
complete EMEM culture medium containing 1 mg/ml puromycin (or relevant antibiotic) 
for Caco2 cells. 
44. After antibiotic selection of transduced cells, select clonal cell lines by isolating single 
cells into 96-well plates through either cell sorting or other isolation procedures (See 
notes 19 and 20). 
45. For single isolation of AML cells, count cells with an automated cell counter and prepare 
a cell suspension with 10
6
 cells/ml in cell sorting buffer. 
46. For single isolation of Caco2 cells, aspirate culture medium and wash cells with room 
temperature PBS. 
47.  Add trypsin/EDTA and incubate for 3 min to detach cells. 
48. Resuspend dissociated cells with prewarmed complete EMEM medium and gently pipet 
up and down several times to generate a single-cell suspension. 
49. Centrifuge the cell suspension for 5 min at 800 g at room temperature. 
50. Aspirate the supernatant and resuspend the cell pellet in appropriate volume of cell 
sorting buffer to adjust the cell concentration to 10
6
 cells/ml. 
51. Filter cell suspensions through a 50 μm filter into a FACS tube. 
52. Set up the cell sorter and install the required collection device. 
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53. Collect cells individually into 96-well plates containing 100 µl/ well of appropriate 
culture medium. 
54. After isolation of single cells (or single-cell derived clones), culture the cells without 
selection antibiotic. Allow the bulk cells to expand in a humidified 37°C, 5% CO2 
incubator. Establishment of new clonal cell lines will vary depending on the doubling 
time of the cell line used. 
Fluorescence-activated cell sorting (FACS) enrichment and clonal isolation 
The following steps are performed for clonal isolation without antibiotic selection when using 
a lentiCRISPR plasmid expressing a fluorescent marker (eg, pL-CRISPR.EFS.GFP plasmid). 
This approach can be a useful alternative strategy when working with puromycin (or other 
antibiotic) resistant cell lines. Indeed, we used FACS to select cells transduced with ‘GFP’ 
pL-CRISPR.EFS.GFP/ AMPK2 in puromycin-resistant AMPK1 knockout Caco2 cells 
(previously generated by transduction with ‘puromycin’ lentiCRISPR/AMPK1) (See note 
21) (Figure 3). 
55. Two to three days after lentiviral transduction, confirm successful delivery of sgRNA by 
visualizing fluorescent marker expression using fluorescence microscopy. 
56. Prepare cells for FACS analysis as described in section 3.3 steps 45 to 51 for suspension 
and adherent cells. 
57. Set up the flow cytometer with negative control cells. Adjust the forward scatter (FSC) 
and side scatter (SSC) to place the population of interest on scale. 
58. Run positive control cells and draw an interval gate to define the populations of interest. 
59. Once gate have been determined, sort the top ~10% of fluorescent positive cells from the 
experimental samples. 
60.  Collect cells individually into 96-well plates containing 100 µl/ well of culture medium. 
61. After sorting, examine the plates under a microscope and determine the presence of a 
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single cell in most of the wells on the plate. Mark off the wells that are empty or that may 
have been seeded more than a single cell. 
62. When cells exceed 105 cells/ml for suspension cells and are 80-90% confluent for 
adherent cells, prepare replicate plates for screening. 
63. Expand the cells for 2–3 weeks. Change medium every 3–5 days as necessary and 
passage accordingly. 
 
[Figure 3 near here] 
 
3.4 Screening and validation 
Most mutations induced by sgRNA at target site are small deletions or insertions (± 1 to 20 
bp) and knockout cell clones can be simply identified by analysing successful micro-deletions 
or -insertions by product size analysis. Forward and reverse primers designed to anneal 
outside of the target locus region are used. 
 
64. Screen a coverage of >20 clones per sgRNA to guarantee that each perturbation will be 
sufficiently represented in the final screening readout. (See note 22). 
Cell lysis 
65. Transfer cells into a 96-well U-bottom plate and wash once in PBS buffer through 
centrifugation at 1200 rpm for 20 seconds at 4°C. 
66.  Discard culture medium and add 13µl of cell lysis buffer. (See notes 23 and 24). 
67.  Transfer into PCR tubes, vortex briefly and heat at 56°C for 10 min and then at 95°C for 
an additional 10 min. 
  
PCR amplification 
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68. Select a 500-bp region around the targeting site and identify optimal targeting primer sets 
that amplify 200 to 300 bp around the targeting site. (See note 25). 
69. Assemble a 50 µl PCR with 13 µl of cell lysate, 1.5 µl of 10 µM 5’-FAM labeled forward 
primer, 1.5 µl of 10 µM non-fluorescent reverse primer, 1 µl of 10 mM dNTP, 10 µl of 
5X PCR buffer and 1 µl of Phire taq polymerase.  
70. Run sample in thermocycler with the following program: 98°C for 1 min and for 35 
cycles:, 98°C for 7 sec, X°C for 5 sec (X depend on the annealing temperature of the 
primers), 72°C for 10-15 sec/ kb, and then 72°C for 1 min. (See note 26). 
71. After the reaction is complete, run 1 μl of each amplified target on a 2% (w/v) agarose gel 
in TAE to verify successful amplification of a single product at the appropriate size. 
 
Fragment analysis 
72. To 1µL of fluorescent PCR products, add 18.8 µL of water and 0.2 µL of GeneScan™ 
500ROX. 
73. Perform migration by capillary electrophoresis using a DNA analyzer. 
74.  Analyse migration profile using GeneMapper® software v3.7 (Applied Biosystems) 
(Figure 4C, left panel). 
 
[Figure 4 near here] 
 
Validation of genetic modification by Sanger sequencing 
75. Use non-fluorescent primers to generate amplicons as described above (steps 68-70). 
76. Sequence the amplicons by using the same primers. Representative chromatograms are 
provided in Figure 4C (right panel) for correlation with fragment analysis for the same 
clone.  
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Verification of knockout cell clones by immunoblotting analysis 
After validation of sequence perturbation, Western blot analysis is recommended for verifying 
protein expression of targeted genes (See note 24). Methods for performing Western blot are 
described in Chapters 24 and 27. 
Western blots from CRISPR/AMPK1-modified MOLM-14- and OCI-AML3-derived clones 
are shown in Figures 5A-C. Western blots from CRISPR/AMPK1- and CRISPR/AMPK2- 
modified Caco2-derived clones are shown in Figure 3A and B. 
 
[Figure 5 near here] 
 
4. Notes 
1. Although we provide a comprehensive view of CRISPR/Cas9 use in human AML and 
colon carcinoma cell lines, the methods described here may be applied to AMPK 
knockdown in other human cell lines as well as to any gene of interest. 
2. Recent breakthrough allows researchers to disrupt the expression of a given gene by 
multiple means. Among the most popular techniques are RNA interference and 
CRISPR/Cas9, whose pros and cons are reviewed by other [12]. While both 
techniques might be used to achieve a partial knockdown of protein expression (for 
example with inactivated dCas9 fused to transcriptional modulators [15]), only 
CRISPR/Cas9 can achieve a complete and stable inhibition of protein expression. We 
believe that most of the technical pitfalls in CRISPR/Cas9 assays could be overcome 
after a careful adaptation of our current canvas to each cell type and sgRNAs, 
providing an invaluable tool for AMPK pharmacological research and beyond.  
3. Many bioinformatics tools are available online to help in the design of sgRNA (e.g., 
ZiFit, CRISPR Design Tool). We used the optimized CRISPR Design application 
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software from Dr Feng Zhang’s laboratory (http://crispr.mit.edu). This software 
provides an accurate analysis of off-target sites. Due to the growing use of the 
CRISPR/Cas9 technology, more and more sgRNA sequences will be published to 
target a given gene/protein. Thus, it will be possible to pick-up already validated 
sgRNA sequences into published articles. Some companies also offers ready-to-use 
plasmids containing a validated sgRNA and also services for lentiviral particle 
production for a given plasmid that may represents a valuable assets, particularly for 
teams with limited experience with the CRISPR/Cas9 technology. 
4. In previous publication, we have used the lentiCRISPRv1 plasmid [10], formerly 
referenced under the Addgene reference #49545, but this plasmid is currently not 
available due to the recent development of lentiCRISPRv2 plasmid (Addgene 
reference #52961). lentiCRISPRv2 is identical to the original lentiCRISPRv1 but 
produces nearly 10-fold higher titer virus. 
5. We mostly used the LentiCRISPR v1 plasmid, allowing the expression of sgRNA and 
Cas9 though a unique vector. While we found this system very convenient for our 
purposes, facilitating the clonal selection steps by antibiotic selection and allowing 
further transductions with other lentiviral vectors, such as GFP-expressing vectors 
(pL-CRISPR.EFS.GFP plasmid, Addgene reference #57818), people may want to use 
different systems dependent on their cellular model. Among many CRISPR/Cas9 tools 
currently available, we mention doxycycline-inducible vectors, such as for example 
the pLKO.1-puro U6 sgRNA BfuAI stuffer plasmid (Addgene #50920), using a 
modified Cas9 inactivated for endonuclease activity (dCas9) and fused to transcription 
co-repressors such as KRAB, allowing a direct and efficient repression of transcription.  
6. Appropriate sgRNA sequences are computationally designed based on known sgRNA 
targeting rules. The selected genomic target sequence should be unique to the genomic 
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target site and be present immediately upstream the PAM sequence that is necessary 
for Cas9 recognition. Cas9 nuclease cuts 3-nt upstream of the PAM site. Avoid target 
sequence with homopolymer stretches (eg, AAAA) and with a GC rich content. The 
sequence analysis software analyses a target sequence of up to 500 nucleotides and 
searches for PAM sequences either in the positive or negative strand of the 
corresponding genomic DNA. Every potential sgRNA is then analysed against a 
reference genome (eg, human genome hg19), to search for potential off-target sites in 
the whole genome. The output assigns a score (from 0 to 100) for each guide, 
according to an algorithm described on the website, and indicates the potential 
undesirable targets of this sgRNA. As recommended by Zhang's team, sgRNA with a 
score above 50 are good candidates, provided the off-targets are outside gene regions. 
7. sgRNA targeting the first exons of the gene are better candidates, to ensure that the 
premature stop codon will efficiently disrupt protein function. However, when 
targeting genes encoding multiple isoforms, we recommend targeting exons shared 
between all isoforms. 
8. It is recommended to check the location of the sgRNA on the genomic sequence of the 
gene of interest, in order to avoid sgRNA that would be complementary to an exon-
exon junction and thus would be inefficient at the genomic level.  
9. If the 20 bp sequence does not start with a ‘G’, a single ‘G’ nucleotide must be 
prepended to allow efficient transcription from the RNA Polymerase III U6 promoter. 
10. Appropriate sites for restriction enzymes should be added for subcloning purpose. If 
plentiCRISPR plasmid contain a Esp3I (BsmBI) restriction site, add ‘GATC’ to the 5’ 
end of the forward sequence and ‘AAAA’ to the 5’ end of reverse complementary 
sequence. The two oligos should anneal to form the following double strand: 
5’-GATCGXXXXXXXXXXXXXXXXXXXXG-3’ 
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 3’-CXXXXXXXXXXXXXXXXXXXXCAAAA-5’ 
11. A control sgRNA that does not match any genomic sequence can be also synthesized. 
We used the following non-targeted guide as a control: 5'-
GTAGGCGCGCCGCTCTCTAC -3' [10]. 
12. We suggest using two (or more) different sgRNA sequences for each target gene, to be 
able to conclude that the observed effects are directly due to gene knockout, rather 
than to off-target activities of the constructs. 
13. If phosphorylated oligonucleotides are ordered, the use of T4 PNK is omitted. 
14. In order to minimize the risk of self-ligation of the plentiCRISPR plasmid, an 
additional digestion with 30 U of NsiI in the presence of 3 U of thermosensitive 
alkaline phosphatase (FastAP, EF0651, Thermo Scientific) is performed. 
15. Lentiviral transfer plasmids contain Long-Terminal Repeats (LTRs) and must be 
transformed into recombination-deficient bacteria. We use Stbl3 E. coli 
(ThermoFisher scientific, C7373-03) although other RecA
- 
strains may be used as 
well. 
16.  The choice between calcium/HBS and lipofectamineTM2000 to transduce HEK293 
cells is mostly based on the cost/efficiency balance. For large lentiviral productions, 
we generally use calcium/HBS transductions for cost/efficiency reasons. In case of 
hard-to-transduce cell line, filtrated and concentrated supernatants should be used in 
priority. Alternatively, lentiviral production can be delegated to commercial 
companies. Lentiviral supernatants should be stored at -80°C and freezing/thawing 
cycles should be avoided by aliquoting the supernatants in small fractions. 
17. Lentivirus supernantants can be concentrated by ultracentrifugation to increase 
transduction efficiency that may be helpful for some cell types. Concentration of 
lentivirus is achieved through centrifugation in a SW32Ti rotor at 22 000 rpm for 1h30 
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with the following settings: acceleration 3; deceleration 3. Concentrated supernatants 
are then stored at -80°C. 
18. Researchers should be aware that lentiviral transduction efficacy is widely different 
across cell line, and that each lentiviral supernatant batch also produces different 
transduction rates for the same cell line. We recommend the determination of a MOI 
for each lentiviral supernatant and each cell line used. MOI calculation is based on 
Poisson’s statistics, assuming that cell transduction is a binary process. Indeed, MOI 
better reflects the true cell transduction rate than quantification of lentiviral particle on 
cell culture supernatants due to the presence of empty particles. While MOI is ideally 
evaluated when the vector is directly detected in a given cell, for example by a 
fluorescent protein (GFP or other), an approximation of efficiently transduced cells is 
possible using antibiotic selection such as puromycin, approximating that only 
transduced cells are alive after adjunction of the selection compound. 
19. Among multiple critical steps using this technique described here, people should keep 
in mind that, dependent on cell type, CRISPR/Cas9-induced knockdown may not be 
apparent in a bulk cellular population, in contrast to other techniques such as RNA 
interference. Several parameters may explain this fact, among which are variability in 
lentiviral transduction efficacy, discrepancy in sgRNA efficacy and also cell ploidy 
that may affect CRISPR/Cas9 efficacy in the presence of multiple copy of a given 
gene. Moreover, CRISPR/Cas9 may induce multiple gene modifications at the single-
cell level, which may be difficult to genetically characterize when working on a bulk 
population. For these reasons, we recommend to single-cell clone transduced cell lines 
and to choose the optimal clones based on genetic and immunoblotting 
characterization. 
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20. Depending on the response of used cell types to FACS, alternative methods can be 
performed. Cells can be individually sorted by using limiting dilution. We recommend 
to plate cells at 0.4 cell/well of 96-well plate. Isolation of clonal cell populations can 
be also performed by platting the cells at low density to isolate individual single-cell 
derived clones. Monoclonal colonies can be picked and moved to a flat bottom 96-
well plate for expansion. As colony formation could vary among cell types, optimal 
density of cell population needs to be determined empirically. 
21. Beyond genetic and proteomic characterization of AMPK knockdown cells, attention 
should be given to the evaluation of AMPK activity in these cells. In AML cells, we 
exploited the fact that only AMPKα1 isoform are expressed, allowing a complete 
disruption of AMPK activity, as attested for example by the absence of induction of 
ACC phosphorylation upon stimulation by AMPK activators [10]. In other cell types, 
co-expression of AMPKα2 even at low levels might represent an issue for achieving a 
complete inhibition of AMPK. In this situation, strategy of sequential targeting of 
PRKAA1 and then PRKAA2 by different CRISPR/Cas9 vectors might represent an 
option. 
22. In our experience, the probability of inducing DNA alterations by CRISPR/Cas9 is 
variable depending on the vector, sgRNA and cell line. Therefore, achieving a 
significant depletion of a target protein on a bulk cellular population by this method is 
uncommon. In MOLM-14 and OCI-AML3 bulk populations, efficient AMPKα1 
knockdown is achieved using AMPK#2 sgRNA but AMPKα1 protein expression is 
barely affected by AMPK#1 sgRNA in these cells (Figure 3A). We may extrapolate 
the probability of efficient knockdown, as in OCI-AML3 cells, 2/12 (16%) clones 
were AMPKα1-depleted with AMPK#1 guide and 7/12 (58%) with AMPK#2 guide 
(Figure 3B). Similar, we found 1/5 (20%) modified clones with AMPK#1 and 5/7 
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(71%) with AMPK#2 in the MOLM-14 cell line (Figure 3C). We thus suggest 
performing a single-cell selection of cellular clones that will be further genetically 
characterized. 
23. We have developed an easy-to-use assay to amplify a region avoiding DNA extraction, 
and using a limited number of cells. This tool allows searching for genomic DNA 
modifications in a large number of single cell-derived clones simultaneously. However, 
any method for genomic DNA isolation may be utilized. 
24. To screen for multiple clones in parallel, we set up an assay based on direct PCR 
amplification of our target genomic sequence among cells in liquid cultures. By direct 
cell lysis into the PCR tube, we avoid time-consuming steps of DNA extraction and 
purification. While we focused on capillary electrophoresis DNA fragment analysis, as 
we found this technique robust and cost-efficient for our purposes, other techniques 
may be applied to characterize CRISPR/Cas9-induced genomic modifications 
including next-generation sequencing [16]. Although time-consuming, it is possible to 
search for protein modification across the clones using immunoblotting. Alternatively, 
we may imagine to directly assess protein expression in single cell clones using 
reverse phase protein microarrays (RPPA) that allows to test in parallel up to 100 
conditions in a single slide [17]. However in this latter case, we still advise to 
characterize the selected clones at the genetic level as well. 
25. Amplification of fragment smaller than 400 bp is recommended to ensure good 
resolution of the fluorescence-labelled DNA size analysis. Note that the size of 
amplicon analysis could vary by ~1 bp. 
26. To estimate the appropriate annealing temperature for primer pairs when using the 
Phire DNA polymerase, we use the Tm calculator application available at 
https://www.thermofisher.com/us/en/home/brands/thermo-scientific/molecular-
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biology/molecular-biology-learning-center/molecular-biology-resource-
library/thermo-scientific-web-tools/tm-calculator.html. 
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Figure captions 
Figure 1. Graphical representation of PRKAA1 and PRKAA2 genomic DNA sequences. 
PRKAA1 and PRKAA2 encompass 9 and 10 exons, respectively, Exons are figured as vertical 
black rectangles. PRKAA1 exon 7 is highlighted in red. Intronic regions are depicted by 
connecting roof-shaped lines. 3’ untranslated regions (3’UTR) are indicated. The scale is 
indicated, 1Kb: 10
3
 bases. (A) AMPKα1 sgRNA#1 (green) and sgRNA#2 (red); forward 
(blue) and reverse (pink) sequencing primers; and predicted amplicon (underlined) are 
represented. (B) AMPKα2 sgRNA 1 (green) and 2 (red); forward (blue) and reverse (pink) 
sequencing primers; and predicted amplicon (underlined) are represented. 
 
Figure 2. Screenshots from online CRISPR design tool. (A) Graphical representation of 
location for proposed AMPKα1 sgRNA sequence within PRKAA1 gene. (B) Specificity 
scores for proposed AMPKα1 sgRNA sequence. Each guide has a specificity score from 0 to 
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100. (C) Details about potential off-targets. CRISPR Design application software is available 
at http://crispr.mit.edu. 
 
Figure 3. Experimental workflow for genome engineering of colon carcinoma Caco2 
cells. We used a sequential procedure to achieve both AMPKα1 and AMPKα2 knockout in 
single-cell Caco2 clones. (A) PRKAA1-targeting sgRNAs are cloned into the pLenti-CRISPR 
plasmid, allowing a selection based on puromycin resistance. PRKAA2-targeting sgRNAs are 
cloned into the pL-CRISPR.EFS.GFP plasmid allowing a selection based on GFP detection. 
Single-cell sgRNA AMPKα1 Caco2 clones were selected based on puromycin resistance (left 
part) and then single-cell sgRNA AMPKα2 Caco2 clones on a AMPKα1 knockout 
background are isolated based on GFP fluorescence (right part). (B) Genome editing 
efficiency of AMPK2 sgRNA in AMPK1-knockout Caco-2 cells is assessed by capillary 
electrophoresis fragment analysis. (C) Western blots analysis of AMPKα protein expression 
in single-cell Caco2 clones isolated after sequential transduction with lentivirus expressing 
‘puromycin’ CRISPR/AMPKα1 and ‘GFP’ CRISPR/AMPKα2. Clone numbers highlighted in 
red and in black indicate successful AMPKα2 knockout and knockout failure, respectively. 
Western blots were performed using anti-panAMPKα and anti-β-actin antibodies. 
 
Figure 4. Fragment and sequencing analysis of single-cell sgRNA AMPKα1 AML clones. 
(A) Limiting dilutions experiments in MOLM-14 cells to assess the sensitivity of H2O/tween 
lysis and AMPKα1 targeted locus amplification. (B) Agarose gel migration of PCR products 
(using the sequencing primers described in Figure 1A) from single-cell MOLM-14 and OCI-
AML3 clones isolated after transduction with lentivirus expressing CRISPR/AMPKα1#1 and 
#2. (C) Capillary electrophoresis fragment analysis using FAM-labelled primers in OCI-
AML3 CTR, OCI-AML3 AMPK1#2_5 and MOLM-14 AMPK1#2_15 clones (left panel) 
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and matching Sanger sequencing for OCI-AML3 AMPK1#2_5 and MOLM-14 
AMPK1#2_15 clones (right panel). 
 
Figure 5. AMPKα1 protein expression in sgRNA AMPK1 AML cell lines. (A) Western 
blot analysis of AMPKα1 protein expression in MOLM-14 and OCI-AML3 cell lines bulk 
populations transduced with lentivirus expressing CRISPR/AMPKα1#1 and #2. (B) Western 
blots analysis of AMPKα1 protein expression in single-cell OCI-AML3 clones after 
transduction with lentivirus expressing CRISPR/AMPKα1#1 and #2. (C) Western blots 
analysis of AMPKα1 protein expression in single-cell MOLM-14 clones isolated after 
transduction with lentivirus expressing CRISPR/AMPKα1#1 and #2. Clone numbers 
highlighted in red and in black indicate successful AMPKα1 knockout and knockout failure, 
respectively. Western blots were performea using anti-AMPKα1 and anti-α-actin antibodies. 
 
 
